Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 1112Recurrence 195Neoplasms 89Lymphoma 89Neoplasms, Plasma Cell 88Lymphoma, Non-Hodgkin 86Leukemia, Myeloid, Acute 53Hematologic Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia 37Myelodysplastic Syndromes 33Lymphoma, Large B-Cell, Diffuse 31Hodgkin Disease 31Immunoglobulin Light-chain Amyloidosis 30Breast Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hematologic Diseases 25Prostatic Neoplasms 19Paraproteinemias 19Lymphoma, B-Cell 19Amyloidosis 19Lymphoma, Mantle-Cell 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Waldenstrom Macroglobulinemia 16Lung Neoplasms 16Lymphoma, Follicular 15Lymphoproliferative Disorders 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Blood Protein Disorders 14

Interventions

repotrectinib 1Suspensions 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solitary Fibrous Tumors × Plasma cell × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡